Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints | Zendy

Marilena Tsala | Zendy; Sophia Vourli | Zendy; Panagiota-Christina Georgiou | Zendy; Spyros Pournaras | Zendy; Athanassios Tsakris | Zendy; George L. Daikos | Zendy; Johan W. Mouton | Zendy; Joseph Meletiadis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints

Author(s) -

Marilena Tsala,

Sophia Vourli,

Panagiota-Christina Georgiou,

Spyros Pournaras,

Athanassios Tsakris,

George L. Daikos,

Johan W. Mouton,

Joseph Meletiadis

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx522

Subject(s) - colistin , pharmacodynamics , dosing , klebsiella pneumoniae , pharmacokinetics , pharmacology , medicine , minimum inhibitory concentration , microbiology and biotechnology , chemistry , antibiotics , biology , escherichia coli , biochemistry , gene

Because the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of colistin against Enterobacteriaceae are not well explored, we studied the activity of colistin against K. pneumoniae in an in vitro PK/PD model simulating different dosing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research